The role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the primary staging of rectal cancer

被引:29
|
作者
Ozis, Salih Erpulat [1 ]
Soydal, Cigdem [2 ]
Akyol, Cihangir [3 ]
Can, Nalan [4 ]
Kucuk, Ozlem Nuriye [2 ]
Yagci, Cemil [5 ]
Erkek, Ayhan Bulent [3 ]
Kuzu, Mehmet Ayhan [3 ]
机构
[1] Ufuk Univ, Fac Med, Dept Surg, Ankara, Turkey
[2] Ankara Univ, Fac Med, Dept Nucl Med, TR-06100 Ankara, Turkey
[3] Ankara Univ, Fac Med, Dept Surg, TR-06100 Ankara, Turkey
[4] Medicana Hosp, Dept Nucl Med, Ankara, Turkey
[5] Ankara Univ, Fac Med, Dept Radiol, TR-06100 Ankara, Turkey
关键词
Rectal cancer; F-18-flourodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography; Primary staging; COLORECTAL-CANCER; FDG-PET/CT; COMPUTED-TOMOGRAPHY; VOLUME DELINEATION; RECURRENCE; IMPACT; RADIOTHERAPY; MANAGEMENT; CT; THERAPY;
D O I
10.1186/1477-7819-12-26
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: In this study we aimed to determine the need for F-18-flourodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in the preoperative staging of rectal carcinoma in our large patient group according to level and location of tumor. Method: Totally, 97 patients diagnosed with primary rectal adenocarcinoma between May 2009 and July 2011 were included in the study. Preoperative staging was performed by evaluating contrast- enhanced thoracic, abdominal, and pelvic computed tomographies. After staging by conventional methods, all patients underwent an F-18-FDG PET/CT. In all cases, the relationship between F-18-FDG uptake and gender, tumor height at the anal canal, localization in the rectal wall, plasma carcinoembryonic antigen levels, histopathological tumor type, and tumor stage were examined. Results: While the ceCT was normal in 4 (4%) patients, it was positive for the rectum in 93 (95%), pelvic lymph nodes in 22 (22%), and distant metastases in 14 (14%) (liver (8), lung (8), bone (2), distant lymph nodes (6), and uterus (1)). Using computed tomography, disease stages were determined as stage 0, 1, 2, 3, and 4 in 4, 8, 48, 23, and 14 patients, respectively; F-18-FDG PET/CT was normal in two (2%) patients. The mean SUVmax of FDG-positive rectal tumors was calculated as 17.31 +/- 9.37. Additionally, F-18-FDG uptake was seen in pelvic lymph nodes in 15 (15%) patients and in distant organs in 24 (24%) patients (liver (9), lung (12), bone (5), distant lymph nodes (11), uterus (1), and sigmoid colon (1)). According to an F-18- FDG PET/CT, 2, 7, 47, 20, and 21 patients were staged as stage 0, 1, 2, 3, and 4, respectively. In 14 patients (14.4%), the stage of the disease was either changed, and there was a need to make adjustments to the patient's treatment strategy (n = 10), or the type of operation was changed (n = 4). In seven patients (0.7%), findings from F-18- FDG PET/CT images did not require any changes of the treatment plan. Conclusion: F-FDG PET/CT provides new findings in addition to conventional techniques in the staging of primary rectal cancer. These findings could change the patients' treatment strategies.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Utility of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in cardiac infections
    Jaleel, Jasim
    Kaushik, Prateek
    Patel, Chetan
    Chandra, Khangembam Bankim
    Yadav, Satyavir
    Siddharthan, Deepti
    [J]. INDIAN JOURNAL OF NUCLEAR MEDICINE, 2023, 38 (02): : 140 - 144
  • [22] Role of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography in restaging of adrenocortical carcinoma
    Ozturk, Hakan
    [J]. REPORTS OF PRACTICAL ONCOLOGY AND RADIOTHERAPY, 2023, 28 (06) : 728 - 736
  • [23] Infected Polycystic Kidney Disease: Role Of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography
    Benouhoud, J.
    Choukry, S.
    Shimi, Y.
    Guensi, A.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S845 - S845
  • [24] 18F-fluorodeoxyglucose positron-emission tomography-computed tomography to diagnose recurrent cancer
    J J You
    K J Cline
    C-S Gu
    K I Pritchard
    I S Dayes
    K Y Gulenchyn
    R I Inculet
    S K Dhesy-Thind
    M A Freeman
    A M Chan
    J A Julian
    M N Levine
    [J]. British Journal of Cancer, 2015, 112 : 1737 - 1743
  • [25] Efficacy of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in evaluating lung cancer recurrence
    Asai, Nobuhiro
    Ohkuni, Yoshihiro
    Shoji, Kazufusa
    Kaneko, Norihiro
    [J]. JORNAL BRASILEIRO DE PNEUMOLOGIA, 2013, 39 (02) : 242 - 244
  • [26] 18F-fluorodeoxyglucose positron-emission tomography-computed tomography to diagnose recurrent cancer
    You, J. J.
    Cline, K. J.
    Gu, C-S
    Pritchard, K. I.
    Dayes, I. S.
    Gulenchyn, K. Y.
    Inculet, R. I.
    Dhesy-Thind, S. K.
    Freeman, M. A.
    Chan, A. M.
    Julian, J. A.
    Levine, M. N.
    [J]. BRITISH JOURNAL OF CANCER, 2015, 112 (11) : 1737 - 1743
  • [27] Role of F-18-Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography Scan in Primary Staging of Breast Cancer Compared to Conventional Staging
    Akepati, Naveen Kumar Reddy
    Abubakar, Zakir Ali
    Bikkina, Prathyusha
    [J]. INDIAN JOURNAL OF NUCLEAR MEDICINE, 2018, 33 (03): : 190 - 193
  • [28] Rare case of primary leiomyosarcoma of bone - Findings on 18F-fluorodeoxyglucose positron emission tomography/computed tomography
    Kumar, Pramit
    Singh, Parneet
    Parida, Girish Kumar
    Singhal, Tejasvini
    Ayyanar, Pavithra
    Pavithra, R.
    Agrawal, Kanhaiyalal
    [J]. INDIAN JOURNAL OF NUCLEAR MEDICINE, 2024, 39 (01): : 52 - 54
  • [29] THE DIAGNOSTIC ACCURACY OF 18F-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY IN STAGING MUSCLE-INVASIVE BLADDER CANCER PATIENTS
    Soubra, Ayman
    Hayward, Daniel
    Goldfarb, Robert
    Dahm, Philipp
    Froelich, Jerry
    Konety, Badrinath
    [J]. JOURNAL OF UROLOGY, 2015, 193 (04): : E844 - E845
  • [30] 18F-fluorodeoxyglucose positron emission tomography-computed tomography as a screening tool for second primary cancers in cancer patients
    Liu, Yang
    Ma, Jie
    Liu, Yingxin
    [J]. ONCOTARGET, 2017, 8 (54) : 92555 - 92560